Study:
A Phase III Trial of CHOP Plus Rituximab vs CHOP Plus Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin`s Lymphomas
Rationale:
Drugs used in chemotherapy work in different ways to stop cancer cells from
dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and
either kill them or deliver radioactive tumor-killing substances to them without harming
normal cells. It is not yet known which monoclonal antibody plus combination chemotherapy
regimen is more effective in treating non-Hodgkin`s lymphoma.
Purpose:
This randomized phase III trial is comparing 2 different monoclonal antibodies
given together with combination chemotherapy to see how well they work in treating patients
with newly-diagnosed non-Hodgkin`s lymphoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Biological: rituximab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: tositumomab and iodine I 131 tositumomab |
Phase 3 |
Verified by
Southwest Oncology Group
January, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00006721
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Oliver W. Press, MD, PhD., Study Chair
Myron S. Czuczman, MD., Study Chair
Sandra J. Horning, MD., Study Chair